home / stock / immx / immx news

IMMX News and Press, Immix Biopharma Inc. From 02/05/24

Stock Information
Company Name: Immix Biopharma Inc.
Stock Symbol: IMMX
Market: NASDAQ
Website: immixbio.com
Menu
IMMX IMMX Quote IMMX Short IMMX News IMMX Articles IMMX Message Board
Get IMMX Alerts

News, Short Squeeze, Breakout and More Instantly...
IMMX - Immix Biopharma Announces Proposed Public Offering of Common Stock

LOS ANGELES, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq: IMMX) (the “Company”), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced that it intends to offer and sell shares of its common stock in an under...
IMMX - Redhill Biopharma, Vera Therapeutics among healthcare movers

2024-01-25 10:00:05 ET More on Health Care Select Sector SPDR Healthcare In 2024: Navigating The Biopharma Bull Run XLV Likely Back To Outperforming XLV: Considering The Low-Maintenance Option To Navigate The Healthcare Sector Investors were most bullish on H...

IMMX - Immix Biopharma Statement On January 2024 FDA Labeling Change Notification For Approved CAR-T Products

LOS ANGELES, CA, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in autoimmune disease, today announced...

IMMX - RUM, ENVB and GAME among mid-day movers

2024-01-23 12:48:13 ET Gainers: Rail Vision Ltd ( RVSN ) +274% . FaZe Holdings ( FAZE ) +100% . Nuvve Holding Corp NVVE +50% . Ensysce Biosciences ENSC +48% . Turnstone Biologics Corp ( TSBX ) +41% . Rumble ( RUM ) +38% . ...
IMMX - Immix Biopharma Announces Dr. Vaishali Sanchorawala, AL Amyloidosis Thought Leader, Director of the Amyloidosis Center at Boston University and Boston Medical Center, Joins Scientific Advisory Board

LOS ANGELES, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix Biopharma”, “Company”, “We” or “Us”, Nasdaq:IMMX), announced that effective today, Vaishali Sanchorawala, MD, has joined ImmixBio subsidiary Nexcella Scientific Adv...

IMMX - Immix Biopharma Announces Dr. Marko Radic, Autoimmune CAR-T Pioneer and Associate Professor at the University of Tennessee Health Science Center, Joins Scientific Advisory Board

Dr. Radic led and authored landmark study demonstrating applicability of CAR-Ts in autoimmune diseases published in Science Translational Medicine , 2019 Dr. Radic is a recognized thought leader in autoimmune CAR-T cell therapy, antibody-mediated disorders and designing CAR-T studies ...

IMMX - BATL, SNCR and BVN are among pre market gainers

2023-12-18 08:17:02 ET Getaround ( GETR ) +85% . Battalion Oil Corp ( BATL ) +82% . Verrica Pharmaceuticals ( VRCA ) +62% . Cardio Diagnostics Holdings ( CDIO ) +45% . Brilliant Acquisition  ( BRLI ) +45% . Northann  ( ...
IMMX - BATL, and TANH among mid-day movers

2023-12-15 13:25:40 ET Gainers: Getaround ( GETR ) +116% . Battalion Oil Corp ( BATL ) +82% . La Rosa Holdings Corp. ( LRHC ) +45% . Verrica Pharmaceuticals ( VRCA ) +37% . Bruush Oral Care ( BRSH ) +36% . NCS Multistage Hold...

IMMX - CAN, TPIC and MOTS among mid-day movers

2023-12-14 12:28:56 ET Gainers: Freight Technologies ( FRGT ) +178% . TPI Composites ( TPIC ) +67% . TriSalus Life Sciences ( TLSI ) +35% . Codexis ( CDXS ) +33% . Canterbury Park Holding Corp ( CPHC ) +33% . Canaan ( CAN ...

IMMX - Immix Biopharma Announces 100% Overall Response Rate (n=10); 23.7 months Best Response Duration (ongoing) for CAR-T NXC-201 in Relapsed/Refractory AL Amyloidosis Patients at ASH 2023

100% (10/10) overall response rate (ORR) and 70% (7/10) complete response (CR) rate observed in standard of care (Dara-CyBorD) relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy in updated Phase 1/2 data as of December 10, 2023 Best responder duration of response...
Previous 10 Next 10